He replaces interim CEO Todd Newton, who was appointed in September 2022. Newton will remain in his role on the Board of Directors at the Marietta, Georgia–based advanced wound care and therapeutic biologics company.
Capper has nearly 30 years of medtech and life sciences experience. He most recently was CEO of BioTelemetry, which Royal Philips acquired for $2.8 billion. Before that, Capper was president and CEO of both Home Diagnostics and CCS Medical. He has held numerous leadership roles at Bayer as well.
“Over the past several months, the search committee has conducted an evaluation of very strong candidates for this role. Our focus has been to find an experienced executive with a track record of delivering results who shares in our enthusiasm for the future of this company,” Kathleen Behrens, chair of the board, said in a news release.
More about the CEO appointment at MiMedx
Behrens described Capper as a proven and dynamic leader that combines a wealth of experience in medtech and a track record of numerous value-creating achievements over the course of his career. “Joe has demonstrated the ability to lead large organizations, drive sustained growth and clearly understands how to maximize the value of an organization.”
With the new CEO appointment, the company’s board of directors has increased to nine members.
“I am extremely excited for the opportunity to lead MiMedx at this pivotal juncture in the company’s evolution,” Capper said.
Capper thinks MiMex possesses key components that are essential for future success: market-leading technology, a rich product pipeline, an experienced commercial leadership team and a strong financial profile. “There is a growing need from clinicians and patients for better solutions to aid in the healing process. With the right strategic focus, targeted investments, and a culture of execution, I am confident MiMedx will be poised for significant growth. I believe there will be no shortage of opportunities for us to expand and profitably scale this business.”